238 related articles for article (PubMed ID: 16044325)
1. Inhibitory effect of triamcinolone acetonide on corneal neovascularization.
Murata M; Shimizu S; Horiuchi S; Taira M
Graefes Arch Clin Exp Ophthalmol; 2006 Feb; 244(2):205-9. PubMed ID: 16044325
[TBL] [Abstract][Full Text] [Related]
2. Drug delivery to the eye through systematic circulation following subconjonctival injection.
Erdurmus M; Durmus M
Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):1061. PubMed ID: 17120002
[No Abstract] [Full Text] [Related]
3. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
4. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
5. VEGF Trap(R1R2) suppresses experimental corneal angiogenesis.
Oliveira HB; Sakimoto T; Javier JA; Azar DT; Wiegand SJ; Jain S; Chang JH
Eur J Ophthalmol; 2010; 20(1):48-54. PubMed ID: 19882518
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.
Aydin E; Kivilcim M; Peyman GA; Esfahani MR; Kazi AA; Sanders DR
Cornea; 2008 May; 27(4):446-53. PubMed ID: 18434849
[TBL] [Abstract][Full Text] [Related]
7. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors.
Ebrahem Q; Minamoto A; Hoppe G; Anand-Apte B; Sears JE
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4935-41. PubMed ID: 17065510
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of plasminogen fragment on experimentally induced neovascularization of rat corneas.
Murata M; Nakagawa M; Takahashi S
Graefes Arch Clin Exp Ophthalmol; 1997 Sep; 235(9):584-6. PubMed ID: 9342609
[TBL] [Abstract][Full Text] [Related]
11. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model.
Gore A; Horwitz V; Cohen M; Gutman H; Cohen L; Gez R; Kadar T; Dachir S
Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
[TBL] [Abstract][Full Text] [Related]
13. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
[TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
15. Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo.
Sharma A; Bettis DI; Cowden JW; Mohan RR
Mol Vis; 2010 Apr; 16():720-8. PubMed ID: 20431722
[TBL] [Abstract][Full Text] [Related]
16. Subconjunctival triamcinolone for the treatment of corneal graft rejection and new vessels.
Athanasiadis Y; Novitskaya E; Nithyanandrajah GA; Sharma A
Cont Lens Anterior Eye; 2009 Feb; 32(1):31-2. PubMed ID: 18693063
[No Abstract] [Full Text] [Related]
17. Inhibition of corneal neovascularization by rapamycin.
Kwon YS; Kim JC
Exp Mol Med; 2006 Apr; 38(2):173-9. PubMed ID: 16672771
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat.
Klotz O; Park JK; Pleyer U; Hartmann C; Baatz H
Graefes Arch Clin Exp Ophthalmol; 2000 Jan; 238(1):88-93. PubMed ID: 10664059
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis.
Kuo CN; Yang LC; Yang CT; Lai CH; Chen MF; Chen CY; Chen CH; Wu PC; Kou HK; Chen YJ; Hung CH; Tsai CB
Exp Eye Res; 2009 Nov; 89(5):678-85. PubMed ID: 19596319
[TBL] [Abstract][Full Text] [Related]
20. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
